INDICATION |
|
LORBRENA® (lorlatinib) is indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test. |
|
Information on FDA-approved tests for the detection of ALK rearrangements in NSCLC is available at http://www.fda.gov/CompanionDiagnostics. | |
IMPORTANT SAFETY INFORMATION |
|
Contraindications: LORBRENA is contraindicated in patients taking strong CYP3A inducers, due to the potential for serious hepatotoxicity. |
|
Risk of Serious Hepatotoxicity with Concomitant Use of Strong CYP3A Inducers:
Severe hepatotoxicity occurred in 10 of 12 healthy subjects receiving a single dose of LORBRENA with multiple daily doses of rifampin, a strong CYP3A inducer. Grade 4 ALT or AST elevations occurred in 50% of subjects, Grade 3 in 33% of subjects, and Grade 2 in 8% of subjects. ALT or AST elevations occurred within 3 days and returned to within normal limits after a median of 15 days (7 to 34 days); median time to recovery in subjects with Grade 3 or 4 or Grade 2 ALT or AST elevations was 18 days and 7 days, respectively. LORBRENA is contraindicated in patients taking strong CYP3A inducers. Discontinue strong CYP3A inducers for 3 plasma half-lives of the strong CYP3A inducer prior to initiating LORBRENA. |
|
Scroll to see additional Important Safety Information. | |
|
Study Design: CROWN is a global, open-label, randomized, multicenter, Phase 3 trial in which 296 adults with previously untreated ALK-positive locally advanced or metastatic NSCLC were randomized 1:1 to receive LORBRENA 100 mg QD (n=149) or crizotinib 250 mg BID (n=147). The primary endpoint of the trial is PFS based on BICR, and secondary endpoints include OS.1,2 | |
SUPERIOR PROGRESSION-FREE SURVIVAL VS CRIZOTINIB1,2 |
 |
 |
|
• |
At the data cut-off, OS data were not mature; there were not enough events to calculate median OS1,2 | |
|
*Based on 1-sided stratified log-rank test.1 | |
MEDIAN PFS NOT REACHED AT 5 YEARS OF FOLLOW-UP4 |
 |
Primary Endpoint |
|
• |
81% reduction (HR=0.19 [95% CI: 0.13-0.27]) in risk of progression or death vs crizotinib (investigator-assessed)4 | |
 | |
LORBRENA HAS 5 YEARS OF CROWN TRIAL SAFETY DATA4 |
Adverse reactions in the primary analysis: |
|
• |
Serious adverse reactions occurred in 34% of the 149 patients treated with LORBRENA; the most frequently reported serious adverse reactions were pneumonia (4.7%), dyspnea (2.7%), respiratory failure (2.7%), cognitive effects (2.0%), and pyrexia (2.0%). Fatal adverse reactions occurred in 3.4% of patients and included pneumonia (0.7%), respiratory failure (0.7%), cardiac failure acute (0.7%), pulmonary embolism (0.7%), and sudden death (0.7%)1 |
|
|
|
• |
The most frequent (≥20%) adverse reactions for LORBRENA and crizotinib, respectively, were edema (56% vs 40%; 4% vs 1.4% [Grade 3 or 4]), weight gain (38% vs 13%; 17% vs 2.1%), peripheral neuropathy (34% vs 15%; 2% vs 0.7%), cognitive effects (21% vs 6%; 2% vs 0%), diarrhea (21% vs 52%; 1.3% vs 0.7%), and dyspnea (20% vs 16%; 2.7% vs 2.1%)1 |
|
|
|
• |
The most frequent (≥30%) laboratory abnormalities for LORBRENA and crizotinib, respectively, were hypertriglyceridemia (95% vs 27%; 22% vs 0% [Grade 3 or 4]), hypercholesterolemia (91% vs 12%; 19% vs 0%), increased creatinine (81% vs 99%; 0.7% vs 2.1%), increased GGT (52% vs 41%; 6% vs 6%), hyperglycemia (48% vs 27%; 7% vs 2.1%), anemia (48% vs 38%; 2% vs 2.8%), increased AST (48% vs 75%; 2% vs 3.5%), increased ALT (44% vs 75%; 2.7% vs 4.3%), increased CPK (39% vs 64%; 2% vs 5%), and hypoalbuminemia (36% vs 61%; 0.7% vs 6%)1 | |
Adverse reactions in the 5-year follow-up analysis: |
|
• |
The safety profile for LORBRENA in the follow-up analysis was consistent with that in the primary analysis. No new safety signals observed4 | | |
INDICATION |
|
LORBRENA is indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test. |
|
Information on FDA-approved tests for the detection of ALK rearrangements in NSCLC is available at http://www.fda.gov/CompanionDiagnostics. | |
IMPORTANT SAFETY INFORMATION (continued) |
|
Central Nervous System (CNS) Effects:
A broad spectrum of CNS effects can occur; overall, CNS effects occurred in 52% of the 476 patients receiving LORBRENA. These included seizures (1.9%, sometimes in conjunction with other neurologic findings), psychotic effects (7%; 0.6% severe [Grade 3 or 4]), and changes in cognitive function (28%; 2.9% severe), mood (including suicidal ideation) (21%; 1.7% severe), speech (11%; 0.6% severe), mental status (1.3%; 1.1% severe), and sleep (12%). Median time to first onset of any CNS effect was 1.4 months (1 day to 3.4 years). Overall, 2.1% and 10% of patients required permanent or temporary discontinuation of LORBRENA, respectively, for a CNS effect; 8% required dose reduction. Withhold and resume at same or reduced dose or permanently discontinue based on severity. |
|
Hyperlipidemia:
Increases in serum cholesterol and triglycerides can occur. Grade 3 or 4 elevations in total cholesterol occurred in 18% and Grade 3 or 4 elevations in triglycerides occurred in 19% of the 476 patients who received LORBRENA. Median time to onset was 15 days for both hypercholesterolemia and hypertriglyceridemia. Approximately 4% and 7% of patients required temporary discontinuation and 1% and 3% of patients required dose reduction of LORBRENA for elevations in cholesterol and in triglycerides in Study B7461001 and Study B7461006, respectively. Eighty-three percent of patients required initiation of lipid-lowering medications, with a median time to onset of start of such medications of 17 days. Initiate or increase the dose of lipid-lowering agents in patients with
hyperlipidemia. Monitor serum cholesterol and triglycerides before initiating LORBRENA, 1 and 2 months after initiating LORBRENA, and periodically thereafter. Withhold and resume at same dose for the first occurrence; resume at same or reduced dose of LORBRENA for recurrence based on severity. |
|
Atrioventricular (AV) Block: PR interval prolongation and AV block can occur. In 476 patients who received LORBRENA at a dose of 100 mg orally once daily and who had a baseline electrocardiography (ECG), 1.9% experienced AV block and 0.2% experienced Grade 3 AV block and underwent pacemaker placement. Monitor ECG prior to initiating LORBRENA and periodically thereafter. Withhold and resume at reduced or same dose in patients who undergo pacemaker placement. Permanently discontinue for recurrence in patients without a pacemaker. |
|
Interstitial Lung Disease (ILD)/Pneumonitis: Severe or life-threatening pulmonary adverse reactions consistent with ILD/pneumonitis can occur. ILD/pneumonitis occurred in 1.9% of patients, including Grade 3 or 4 ILD/pneumonitis in 0.6% of patients. Four patients (0.8%) discontinued LORBRENA for ILD/pneumonitis. Promptly investigate for ILD/pneumonitis in any patient who presents with worsening of respiratory symptoms indicative of ILD/pneumonitis (e.g., dyspnea, cough, and fever). Immediately withhold LORBRENA in patients with suspected ILD/pneumonitis. Permanently discontinue LORBRENA for treatment-related ILD/pneumonitis of any severity. |
|
Hypertension: Hypertension can occur. Hypertension occurred in 13% of patients, including Grade 3 or 4 in 6% of patients. Median time to onset of hypertension was 6.4 months (1 day to 2.8 years), and 2.3% of patients temporarily discontinued LORBRENA for hypertension. Control blood pressure prior to initiating LORBRENA. Monitor blood pressure after 2 weeks and at least monthly thereafter. Withhold and resume at reduced dose or permanently discontinue based on severity. |
|
Hyperglycemia: Hyperglycemia can occur. Hyperglycemia occurred in 9% of patients, including Grade 3 or 4 in 3.2% of patients. Median time to onset of hyperglycemia was 4.8 months (1 day to 2.9 years), and 0.8% of patients temporarily discontinued LORBRENA for hyperglycemia. Assess fasting serum glucose prior to initiating LORBRENA and monitor periodically thereafter. Withhold and resume at reduced dose or permanently discontinue based on severity. |
|
Embryo-fetal Toxicity: LORBRENA can cause fetal harm. Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to use an effective non-hormonal method of contraception, since LORBRENA can render hormonal contraceptives ineffective, during treatment with LORBRENA and for at least 6 months after the final dose. Advise males with female partners of reproductive potential to use effective contraception during treatment with LORBRENA and for 3 months after the final dose. |
|
Adverse Reactions: In the pooled safety population of 476 patients who received 100 mg LORBRENA once daily, the most frequent (≥ 20%) adverse reactions were edema (56%), peripheral neuropathy (44%), weight gain (31%), cognitive effects (28%), fatigue (27%), dyspnea (27%), arthralgia (24%), diarrhea (23%), mood effects (21%), and cough (21%). The most frequent (≥ 20%) Grade 3-4 laboratory abnormalities in patients receiving LORBRENA were hypercholesterolemia (21%) and hypertriglyceridemia (21%). |
|
In previously untreated patients, serious adverse reactions occurred in 34% of the 149 patients treated with LORBRENA; the most frequently reported serious adverse reactions were pneumonia (4.7%), dyspnea (2.7%), respiratory failure (2.7%), cognitive effects (2.0%), and pyrexia (2.0%). Fatal adverse reactions occurred in 3.4% of patients and included pneumonia (0.7%), respiratory failure (0.7%), cardiac failure acute (0.7%), pulmonary embolism (0.7%), and sudden death (0.7%). In the Phase 1/2 study, serious adverse reactions occurred in 32% of the 295 patients; the most frequently reported serious adverse reactions were pneumonia (3.4%), dyspnea (2.7%), pyrexia (2%), mental status changes (1.4%), and respiratory failure (1.4%). Fatal adverse reactions occurred in 2.7% of
patients and included pneumonia (0.7%), myocardial infarction (0.7%), acute pulmonary edema (0.3%), embolism (0.3%), peripheral artery occlusion (0.3%), and respiratory distress (0.3%). |
|
Drug Interactions: LORBRENA is contraindicated in patients taking strong CYP3A inducers. Avoid concomitant use with moderate CYP3A inducers, strong CYP3A inhibitors, and fluconazole. If concomitant use of moderate CYP3A inducers cannot be avoided, increase the LORBRENA dose as recommended. If concomitant use with a strong CYP3A inhibitor or fluconazole cannot be avoided, reduce the LORBRENA dose as recommended. Avoid concomitant use of LORBRENA with CYP3A substrates and P-gp substrates, which may reduce the efficacy of these substrates. |
|
Lactation: Because of the potential for serious adverse reactions in breastfed infants, instruct women not to breastfeed during treatment with LORBRENA and for 7 days after the final dose. |
|
Hepatic Impairment: No dose adjustment is recommended for patients with mild hepatic impairment. The recommended dose of LORBRENA has not been established for patients with moderate or severe hepatic impairment. |
|
Renal Impairment: Reduce the dose of LORBRENA for patients with severe renal impairment. No dose adjustment is recommended for patients with mild or moderate renal impairment. |
|
Please see full Prescribing Information for LORBRENA. |
|
ALK=anaplastic lymphoma kinase; ALT=alanine aminotransferase; AST=aspartate aminotransferase; BICR=Blinded Independent Central Review; BID=twice daily; CI=confidence interval; CPK=creatine phosphokinase; GGT=gamma-glutamyl transferase; HR=hazard ratio; mNSCLC=metastatic non–small cell lung cancer; NR=not reached; NSCLC=non–small cell lung cancer; OS=overall survival; PFS=progression-free survival; QD=once daily. |
|
References: 1. LORBRENA® (lorlatinib) Prescribing Information. Pfizer Inc.; August 2024. 2. Shaw AT, Bauer TM, de Marinis F, et al; CROWN Trial Investigators. First-line lorlatinib or crizotinib in advanced ALK-positive lung cancer. N Engl J Med. 2020;383(21):2018-2029. 3. Data on file. Pfizer Inc. 4. Solomon BJ, Liu G, Felip E, et al. Lorlatinib versus crizotinib in patients with advanced ALK
-positive non–small cell lung cancer: 5-year outcomes from the Phase III CROWN study. J Clin Oncol. 2024;42(29):3400-3409. |
|
Please do not reply, as this email address cannot accept replies. If you wish to contact Pfizer, click here. |
|
View the Pfizer Privacy Policy here. |
Pfizer, Attn: LORBRENA
P.O. Box 29309
Mission, KS 66201 |
|
This advertisement is intended only for healthcare professionals in the United States. |
|
You are encouraged to report adverse events related to Pfizer products by calling 1-800-438-1985 (US only). If you prefer, you may contact the US Food and Drug Administration (FDA) directly. Visit www.fda.gov/MedWatch or call 1-800-FDA-1088. | | |
|
